Vigmed Holding AB publishes Financial Objectives

Vigmed has recently launched its first commercially available product line, CLiP®, to the European market. The launch of a second product line, SWiNG, will follow during the second half of 2014. As the Company now enters into a commercialization phase, the Board of Directors has decided to submit a first public insight into the Financial Objectives of Vigmed Holding AB.

When evaluating the Financial Objectives of Vigmed given below, its vital to understand the assumptions behind the figures, these are; (1) only product lines within the CLiP® and SWiNG brands plus the third product line to be produced at AMB Industri AB from 2015/16 are included in the calculations, (2) the only markets included are those of Europe and the Americas, (3) market launches will take place as planned.

It should be noted that Vigmed during the period in question also intends to launch additional product lines and introduce its products to markets such as China and other Countries. Financial contributions from these areas have not been included in the Financial Objectives presented now.

Based on the assumptions given above Vigmed, has a Financial Objective to deliver a Net Revenue of SEK 400-600 million in 2018 with a margin level of Earnings before Tax (EBT) of 13-17%. The more traditional measurement of EBIT is somewhat less relevant for Vigmed considering its chosen business model of controlled outsourcing of manufacturing and distribution (for further information see www.vigmed.com, slide 14).

For the start-up year of 2014 Vigmed expects to reach a Net Revenue of SEK 5-10 million with a negative Result and Cash-flow.

For further information contact:

Chairman of the board, Lennart Holm +46 70-630 8562 or CEO, Finn Ketler +46 42 600 5311

Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden, and has approximately 15 employees. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately
5 400 shareholders. Remium Nordic AB is the Company’s Certified Advisor.

Additional information such as company description, a video presentation and risk factors can be found on Vigmed’s website: www.vigmed.com/investor

Tags: